Ultragenyx Pharmaceutical Inc. (RARE) Stock Competitors & Peer Comparison
See (RARE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RARE | $33.82 | -2.28% | 3.3B | -5.54 | -$6.11 | N/A |
| VRTX | $485.39 | -2.24% | 123.2B | 25.79 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $664.52 | -0.51% | 68.5B | 14.56 | $45.63 | +0.55% |
| ARGX | $877.62 | -3.50% | 54.6B | 79.21 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $298.76 | -4.49% | 39.9B | 53.83 | $5.55 | N/A |
| RVMD | $186.88 | -2.22% | 39.7B | -26.43 | -$7.07 | N/A |
| RVMDW | $9.36 | -4.65% | 39.1B | -2.26 | -$4.15 | N/A |
| ONC | $298.70 | -1.36% | 31.9B | 66.82 | $4.47 | N/A |
Stock Comparison
RARE vs VRTX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, VRTX has a market cap of 123.2B. Regarding current trading prices, RARE is priced at $33.82, while VRTX trades at $485.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas VRTX's P/E ratio is 25.79. In terms of profitability, RARE's ROE is +15.67%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, RARE is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check VRTX's competition here
RARE vs VRNA Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RARE is priced at $33.82, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RARE's ROE is +15.67%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, RARE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check VRNA's competition here
RARE vs REGN Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, REGN has a market cap of 68.5B. Regarding current trading prices, RARE is priced at $33.82, while REGN trades at $664.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas REGN's P/E ratio is 14.56. In terms of profitability, RARE's ROE is +15.67%, compared to REGN's ROE of +0.14%. Regarding short-term risk, RARE is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check REGN's competition here
RARE vs ARGX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ARGX has a market cap of 54.6B. Regarding current trading prices, RARE is priced at $33.82, while ARGX trades at $877.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ARGX's P/E ratio is 79.21. In terms of profitability, RARE's ROE is +15.67%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, RARE is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ARGX's competition here
RARE vs SGEN Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RARE is priced at $33.82, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RARE's ROE is +15.67%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RARE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check SGEN's competition here
RARE vs ALNY Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ALNY has a market cap of 39.9B. Regarding current trading prices, RARE is priced at $33.82, while ALNY trades at $298.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ALNY's P/E ratio is 53.83. In terms of profitability, RARE's ROE is +15.67%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, RARE is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ALNY's competition here
RARE vs RVMD Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, RVMD has a market cap of 39.7B. Regarding current trading prices, RARE is priced at $33.82, while RVMD trades at $186.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas RVMD's P/E ratio is -26.43. In terms of profitability, RARE's ROE is +15.67%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, RARE is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RVMD's competition here
RARE vs RVMDW Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, RVMDW has a market cap of 39.1B. Regarding current trading prices, RARE is priced at $33.82, while RVMDW trades at $9.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas RVMDW's P/E ratio is -2.26. In terms of profitability, RARE's ROE is +15.67%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, RARE is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check RVMDW's competition here
RARE vs ONC Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ONC has a market cap of 31.9B. Regarding current trading prices, RARE is priced at $33.82, while ONC trades at $298.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ONC's P/E ratio is 66.82. In terms of profitability, RARE's ROE is +15.67%, compared to ONC's ROE of +0.12%. Regarding short-term risk, RARE is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ONC's competition here
RARE vs MRNA Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, MRNA has a market cap of 27.1B. Regarding current trading prices, RARE is priced at $33.82, while MRNA trades at $68.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas MRNA's P/E ratio is -8.38. In terms of profitability, RARE's ROE is +15.67%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, RARE is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MRNA's competition here
RARE vs ROIV Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ROIV has a market cap of 25.9B. Regarding current trading prices, RARE is priced at $33.82, while ROIV trades at $35.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ROIV's P/E ratio is -36.97. In terms of profitability, RARE's ROE is +15.67%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, RARE is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ROIV's competition here
RARE vs INSM Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, INSM has a market cap of 25.1B. Regarding current trading prices, RARE is priced at $33.82, while INSM trades at $115.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas INSM's P/E ratio is -20.11. In terms of profitability, RARE's ROE is +15.67%, compared to INSM's ROE of -1.30%. Regarding short-term risk, RARE is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check INSM's competition here
RARE vs INCY Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, INCY has a market cap of 23.3B. Regarding current trading prices, RARE is priced at $33.82, while INCY trades at $116.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas INCY's P/E ratio is 15.69. In terms of profitability, RARE's ROE is +15.67%, compared to INCY's ROE of +0.29%. Regarding short-term risk, RARE is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check INCY's competition here
RARE vs UTHR Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, UTHR has a market cap of 23.2B. Regarding current trading prices, RARE is priced at $33.82, while UTHR trades at $547.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas UTHR's P/E ratio is 20.19. In terms of profitability, RARE's ROE is +15.67%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RARE is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check UTHR's competition here
RARE vs BNTX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, BNTX has a market cap of 23.1B. Regarding current trading prices, RARE is priced at $33.82, while BNTX trades at $91.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas BNTX's P/E ratio is -19.80. In terms of profitability, RARE's ROE is +15.67%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, RARE is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BNTX's competition here
RARE vs BGNE Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RARE is priced at $33.82, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RARE's ROE is +15.67%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, RARE is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BGNE's competition here
RARE vs DNA-WT Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RARE is priced at $33.82, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RARE's ROE is +15.67%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, RARE is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check DNA-WT's competition here
RARE vs NBIX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, NBIX has a market cap of 17.8B. Regarding current trading prices, RARE is priced at $33.82, while NBIX trades at $177.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas NBIX's P/E ratio is 25.59. In terms of profitability, RARE's ROE is +15.67%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, RARE is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check NBIX's competition here
RARE vs GMAB Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, GMAB has a market cap of 17.8B. Regarding current trading prices, RARE is priced at $33.82, while GMAB trades at $29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas GMAB's P/E ratio is 20.86. In terms of profitability, RARE's ROE is +15.67%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, RARE is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check GMAB's competition here
RARE vs BBIO Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, BBIO has a market cap of 16.8B. Regarding current trading prices, RARE is priced at $33.82, while BBIO trades at $85.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas BBIO's P/E ratio is -22.97. In terms of profitability, RARE's ROE is +15.67%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, RARE is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check BBIO's competition here
RARE vs ASND Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ASND has a market cap of 16.8B. Regarding current trading prices, RARE is priced at $33.82, while ASND trades at $270.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ASND's P/E ratio is -111.76. In terms of profitability, RARE's ROE is +15.67%, compared to ASND's ROE of -56.42%. Regarding short-term risk, RARE is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ASND's competition here
RARE vs JAZZ Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, JAZZ has a market cap of 15.3B. Regarding current trading prices, RARE is priced at $33.82, while JAZZ trades at $243.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas JAZZ's P/E ratio is 18.96. In terms of profitability, RARE's ROE is +15.67%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, RARE is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check JAZZ's competition here
RARE vs EXEL Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, EXEL has a market cap of 14.2B. Regarding current trading prices, RARE is priced at $33.82, while EXEL trades at $56.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas EXEL's P/E ratio is 16.92. In terms of profitability, RARE's ROE is +15.67%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, RARE is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check EXEL's competition here
RARE vs KRTX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RARE is priced at $33.82, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RARE's ROE is +15.67%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RARE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check KRTX's competition here
RARE vs MDGL Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, MDGL has a market cap of 12.4B. Regarding current trading prices, RARE is priced at $33.82, while MDGL trades at $536.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas MDGL's P/E ratio is -41.93. In terms of profitability, RARE's ROE is +15.67%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, RARE is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MDGL's competition here
RARE vs AXSM Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, AXSM has a market cap of 12B. Regarding current trading prices, RARE is priced at $33.82, while AXSM trades at $233.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas AXSM's P/E ratio is -61.04. In terms of profitability, RARE's ROE is +15.67%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, RARE is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check AXSM's competition here
RARE vs SMMT Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, SMMT has a market cap of 11.8B. Regarding current trading prices, RARE is priced at $33.82, while SMMT trades at $15.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas SMMT's P/E ratio is -9.53. In terms of profitability, RARE's ROE is +15.67%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, RARE is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check SMMT's competition here
RARE vs BMRN Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, BMRN has a market cap of 11.4B. Regarding current trading prices, RARE is priced at $33.82, while BMRN trades at $59.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas BMRN's P/E ratio is 28.42. In terms of profitability, RARE's ROE is +15.67%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, RARE is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BMRN's competition here
RARE vs RNAM Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, RARE is priced at $33.82, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas RNAM's P/E ratio is -17.39. In terms of profitability, RARE's ROE is +15.67%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, RARE is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RNAM's competition here
RARE vs TECH Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, RARE is priced at $33.82, while TECH trades at $71.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas TECH's P/E ratio is 36.75. In terms of profitability, RARE's ROE is +15.67%, compared to TECH's ROE of +0.05%. Regarding short-term risk, RARE is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check TECH's competition here
RARE vs KRYS Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, KRYS has a market cap of 10.8B. Regarding current trading prices, RARE is priced at $33.82, while KRYS trades at $365.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas KRYS's P/E ratio is 48.91. In terms of profitability, RARE's ROE is +15.67%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RARE is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check KRYS's competition here
RARE vs ARWR Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ARWR has a market cap of 10.8B. Regarding current trading prices, RARE is priced at $33.82, while ARWR trades at $76.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ARWR's P/E ratio is -35.53. In terms of profitability, RARE's ROE is +15.67%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, RARE is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ARWR's competition here
RARE vs CYTK Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, CYTK has a market cap of 10.6B. Regarding current trading prices, RARE is priced at $33.82, while CYTK trades at $84.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas CYTK's P/E ratio is -14.56. In terms of profitability, RARE's ROE is +15.67%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, RARE is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CYTK's competition here
RARE vs ABVX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ABVX has a market cap of 10.3B. Regarding current trading prices, RARE is priced at $33.82, while ABVX trades at $139.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ABVX's P/E ratio is -73.17. In terms of profitability, RARE's ROE is +15.67%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, RARE is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ABVX's competition here
RARE vs CORT Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, CORT has a market cap of 9.9B. Regarding current trading prices, RARE is priced at $33.82, while CORT trades at $91.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas CORT's P/E ratio is 262.51. In terms of profitability, RARE's ROE is +15.67%, compared to CORT's ROE of +0.08%. Regarding short-term risk, RARE is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CORT's competition here
RARE vs KYMR Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, KYMR has a market cap of 9.8B. Regarding current trading prices, RARE is priced at $33.82, while KYMR trades at $119.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas KYMR's P/E ratio is -33.81. In terms of profitability, RARE's ROE is +15.67%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, RARE is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check KYMR's competition here
RARE vs IONS Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, IONS has a market cap of 9.6B. Regarding current trading prices, RARE is priced at $33.82, while IONS trades at $58.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas IONS's P/E ratio is -33.87. In terms of profitability, RARE's ROE is +15.67%, compared to IONS's ROE of -0.59%. Regarding short-term risk, RARE is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check IONS's competition here
RARE vs RXDX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RARE is priced at $33.82, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RARE's ROE is +15.67%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RARE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RXDX's competition here
RARE vs NUVL Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, RARE is priced at $33.82, while NUVL trades at $123.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas NUVL's P/E ratio is -21.78. In terms of profitability, RARE's ROE is +15.67%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, RARE is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check NUVL's competition here
RARE vs HALO Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, HALO has a market cap of 9B. Regarding current trading prices, RARE is priced at $33.82, while HALO trades at $76.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas HALO's P/E ratio is 16.49. In terms of profitability, RARE's ROE is +15.67%, compared to HALO's ROE of +1.26%. Regarding short-term risk, RARE is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check HALO's competition here
RARE vs CRNX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, RARE is priced at $33.82, while CRNX trades at $83.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas CRNX's P/E ratio is -16.29. In terms of profitability, RARE's ROE is +15.67%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, RARE is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CRNX's competition here
RARE vs TGTX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, TGTX has a market cap of 8.7B. Regarding current trading prices, RARE is priced at $33.82, while TGTX trades at $57.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas TGTX's P/E ratio is 19.63. In terms of profitability, RARE's ROE is +15.67%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, RARE is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check TGTX's competition here
RARE vs IMGN Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RARE is priced at $33.82, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RARE's ROE is +15.67%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RARE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check IMGN's competition here
RARE vs ALKS Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ALKS has a market cap of 8.7B. Regarding current trading prices, RARE is priced at $33.82, while ALKS trades at $51.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ALKS's P/E ratio is 54.67. In terms of profitability, RARE's ROE is +15.67%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, RARE is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ALKS's competition here
RARE vs IBRX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, IBRX has a market cap of 8.6B. Regarding current trading prices, RARE is priced at $33.82, while IBRX trades at $8.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas IBRX's P/E ratio is -25.69. In terms of profitability, RARE's ROE is +15.67%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, RARE is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check IBRX's competition here
RARE vs PTGX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, RARE is priced at $33.82, while PTGX trades at $131.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas PTGX's P/E ratio is -72.61. In terms of profitability, RARE's ROE is +15.67%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, RARE is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check PTGX's competition here
RARE vs PCVX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, RARE is priced at $33.82, while PCVX trades at $58.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas PCVX's P/E ratio is -8.46. In terms of profitability, RARE's ROE is +15.67%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, RARE is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check PCVX's competition here
RARE vs BPMC Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RARE is priced at $33.82, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RARE's ROE is +15.67%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, RARE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BPMC's competition here
RARE vs APGE Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, RARE is priced at $33.82, while APGE trades at $133.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas APGE's P/E ratio is -30.87. In terms of profitability, RARE's ROE is +15.67%, compared to APGE's ROE of -0.33%. Regarding short-term risk, RARE is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check APGE's competition here
RARE vs CERE Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RARE is priced at $33.82, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas CERE's P/E ratio is -16.47. In terms of profitability, RARE's ROE is +15.67%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RARE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CERE's competition here
RARE vs IMVT Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, RARE is priced at $33.82, while IMVT trades at $39.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas IMVT's P/E ratio is -14.87. In terms of profitability, RARE's ROE is +15.67%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, RARE is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check IMVT's competition here
RARE vs RYTM Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, RYTM has a market cap of 7.4B. Regarding current trading prices, RARE is priced at $33.82, while RYTM trades at $108.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas RYTM's P/E ratio is -34.63. In terms of profitability, RARE's ROE is +15.67%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, RARE is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RYTM's competition here
RARE vs MTSR Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RARE is priced at $33.82, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RARE's ROE is +15.67%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, RARE is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MTSR's competition here
RARE vs LQDA Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, LQDA has a market cap of 7.2B. Regarding current trading prices, RARE is priced at $33.82, while LQDA trades at $77.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas LQDA's P/E ratio is 581.79. In terms of profitability, RARE's ROE is +15.67%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, RARE is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check LQDA's competition here
RARE vs PTCT Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, PTCT has a market cap of 7B. Regarding current trading prices, RARE is priced at $33.82, while PTCT trades at $84.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas PTCT's P/E ratio is -36.42. In terms of profitability, RARE's ROE is +15.67%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, RARE is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check PTCT's competition here
RARE vs PRAX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, RARE is priced at $33.82, while PRAX trades at $324.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas PRAX's P/E ratio is -24.31. In terms of profitability, RARE's ROE is +15.67%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, RARE is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check PRAX's competition here
RARE vs MRUS Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RARE is priced at $33.82, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RARE's ROE is +15.67%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, RARE is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MRUS's competition here
RARE vs SRRK Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, SRRK has a market cap of 6.8B. Regarding current trading prices, RARE is priced at $33.82, while SRRK trades at $56.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas SRRK's P/E ratio is -15.80. In terms of profitability, RARE's ROE is +15.67%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, RARE is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check SRRK's competition here
RARE vs ACLX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RARE is priced at $33.82, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RARE's ROE is +15.67%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RARE is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ACLX's competition here
RARE vs COGT Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, COGT has a market cap of 6.6B. Regarding current trading prices, RARE is priced at $33.82, while COGT trades at $38.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas COGT's P/E ratio is -18.42. In terms of profitability, RARE's ROE is +15.67%, compared to COGT's ROE of -0.83%. Regarding short-term risk, RARE is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check COGT's competition here
RARE vs CGON Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, RARE is priced at $33.82, while CGON trades at $75.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas CGON's P/E ratio is -32.29. In terms of profitability, RARE's ROE is +15.67%, compared to CGON's ROE of -0.23%. Regarding short-term risk, RARE is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CGON's competition here
RARE vs RETA Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RARE is priced at $33.82, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas RETA's P/E ratio is -66.29. In terms of profitability, RARE's ROE is +15.67%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RARE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RETA's competition here
RARE vs LGND Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, LGND has a market cap of 6.5B. Regarding current trading prices, RARE is priced at $33.82, while LGND trades at $316.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas LGND's P/E ratio is 38.68. In terms of profitability, RARE's ROE is +15.67%, compared to LGND's ROE of +0.16%. Regarding short-term risk, RARE is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check LGND's competition here
RARE vs CNTA Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, RARE is priced at $33.82, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas CNTA's P/E ratio is -22.63. In terms of profitability, RARE's ROE is +15.67%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, RARE is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CNTA's competition here
RARE vs MIRM Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, RARE is priced at $33.82, while MIRM trades at $122.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas MIRM's P/E ratio is -8.97. In terms of profitability, RARE's ROE is +15.67%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, RARE is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MIRM's competition here
RARE vs BLTE Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, BLTE has a market cap of 6B. Regarding current trading prices, RARE is priced at $33.82, while BLTE trades at $149.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas BLTE's P/E ratio is -79.86. In terms of profitability, RARE's ROE is +15.67%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, RARE is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BLTE's competition here
RARE vs SYRE Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, SYRE has a market cap of 5.9B. Regarding current trading prices, RARE is priced at $33.82, while SYRE trades at $97.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas SYRE's P/E ratio is -46.99. In terms of profitability, RARE's ROE is +15.67%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, RARE is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check SYRE's competition here
RARE vs ERAS Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ERAS has a market cap of 5.8B. Regarding current trading prices, RARE is priced at $33.82, while ERAS trades at $18.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ERAS's P/E ratio is -42.11. In terms of profitability, RARE's ROE is +15.67%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, RARE is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ERAS's competition here
RARE vs CDTX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RARE is priced at $33.82, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RARE's ROE is +15.67%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, RARE is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CDTX's competition here
RARE vs ABCM Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RARE is priced at $33.82, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RARE's ROE is +15.67%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RARE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ABCM's competition here
RARE vs ISEE Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RARE is priced at $33.82, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RARE's ROE is +15.67%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RARE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ISEE's competition here
RARE vs XENE Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, XENE has a market cap of 5.4B. Regarding current trading prices, RARE is priced at $33.82, while XENE trades at $68.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas XENE's P/E ratio is -14.66. In terms of profitability, RARE's ROE is +15.67%, compared to XENE's ROE of -0.49%. Regarding short-term risk, RARE is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check XENE's competition here
RARE vs TVTX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, RARE is priced at $33.82, while TVTX trades at $56.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas TVTX's P/E ratio is -257.23. In terms of profitability, RARE's ROE is +15.67%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, RARE is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check TVTX's competition here
RARE vs APLS Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, RARE is priced at $33.82, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas APLS's P/E ratio is 38.35. In terms of profitability, RARE's ROE is +15.67%, compared to APLS's ROE of +0.40%. Regarding short-term risk, RARE is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check APLS's competition here
RARE vs CELC Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, CELC has a market cap of 5.2B. Regarding current trading prices, RARE is priced at $33.82, while CELC trades at $107.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas CELC's P/E ratio is -27.58. In terms of profitability, RARE's ROE is +15.67%, compared to CELC's ROE of -2.45%. Regarding short-term risk, RARE is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CELC's competition here
RARE vs CRSP Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, RARE is priced at $33.82, while CRSP trades at $53.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas CRSP's P/E ratio is -10.44. In terms of profitability, RARE's ROE is +15.67%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, RARE is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CRSP's competition here
RARE vs DFTX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, DFTX has a market cap of 5.1B. Regarding current trading prices, RARE is priced at $33.82, while DFTX trades at $47.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas DFTX's P/E ratio is N/A. In terms of profitability, RARE's ROE is +15.67%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, RARE is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check DFTX's competition here
RARE vs LEGN Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, LEGN has a market cap of 5.1B. Regarding current trading prices, RARE is priced at $33.82, while LEGN trades at $27.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas LEGN's P/E ratio is -40.26. In terms of profitability, RARE's ROE is +15.67%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, RARE is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check LEGN's competition here
RARE vs MANE Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, MANE has a market cap of 5B. Regarding current trading prices, RARE is priced at $33.82, while MANE trades at $119.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas MANE's P/E ratio is -38.07. In terms of profitability, RARE's ROE is +15.67%, compared to MANE's ROE of -0.84%. Regarding short-term risk, RARE is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MANE's competition here
RARE vs EWTX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, RARE is priced at $33.82, while EWTX trades at $45.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas EWTX's P/E ratio is -27.36. In terms of profitability, RARE's ROE is +15.67%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, RARE is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check EWTX's competition here
RARE vs CAI Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, CAI has a market cap of 4.8B. Regarding current trading prices, RARE is priced at $33.82, while CAI trades at $16.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas CAI's P/E ratio is -93.45. In terms of profitability, RARE's ROE is +15.67%, compared to CAI's ROE of +0.06%. Regarding short-term risk, RARE is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CAI's competition here
RARE vs TERN Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RARE is priced at $33.82, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas TERN's P/E ratio is -51.41. In terms of profitability, RARE's ROE is +15.67%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RARE is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check TERN's competition here
RARE vs FOLD Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $33.82, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RARE's ROE is +15.67%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RARE is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check FOLD's competition here
RARE vs VKTX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, VKTX has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $33.82, while VKTX trades at $38.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas VKTX's P/E ratio is -9.39. In terms of profitability, RARE's ROE is +15.67%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, RARE is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check VKTX's competition here
RARE vs AKRO Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $33.82, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RARE's ROE is +15.67%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, RARE is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check AKRO's competition here
RARE vs ACAD Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ACAD has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $33.82, while ACAD trades at $26.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ACAD's P/E ratio is 12.85. In terms of profitability, RARE's ROE is +15.67%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, RARE is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ACAD's competition here
RARE vs ALPN Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $33.82, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RARE's ROE is +15.67%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RARE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ALPN's competition here
RARE vs OPT Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RARE is priced at $33.82, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas OPT's P/E ratio is -1.52. In terms of profitability, RARE's ROE is +15.67%, compared to OPT's ROE of +1.18%. Regarding short-term risk, RARE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check OPT's competition here
RARE vs NAMSW Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, NAMSW has a market cap of 4.2B. Regarding current trading prices, RARE is priced at $33.82, while NAMSW trades at $24.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas NAMSW's P/E ratio is -13.76. In terms of profitability, RARE's ROE is +15.67%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, RARE is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check NAMSW's competition here
RARE vs NAMS Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, NAMS has a market cap of 4.1B. Regarding current trading prices, RARE is priced at $33.82, while NAMS trades at $35.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas NAMS's P/E ratio is -22.18. In terms of profitability, RARE's ROE is +15.67%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, RARE is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check NAMS's competition here
RARE vs MRTX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RARE is priced at $33.82, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RARE's ROE is +15.67%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RARE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MRTX's competition here
RARE vs DNLI Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, DNLI has a market cap of 4.1B. Regarding current trading prices, RARE is priced at $33.82, while DNLI trades at $25.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas DNLI's P/E ratio is -8.92. In terms of profitability, RARE's ROE is +15.67%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, RARE is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check DNLI's competition here
RARE vs DNTH Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, DNTH has a market cap of 4.1B. Regarding current trading prices, RARE is priced at $33.82, while DNTH trades at $97.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas DNTH's P/E ratio is -23.63. In terms of profitability, RARE's ROE is +15.67%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, RARE is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check DNTH's competition here
RARE vs DYN Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, DYN has a market cap of 3.9B. Regarding current trading prices, RARE is priced at $33.82, while DYN trades at $23.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas DYN's P/E ratio is -7.27. In terms of profitability, RARE's ROE is +15.67%, compared to DYN's ROE of -0.58%. Regarding short-term risk, RARE is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check DYN's competition here
RARE vs TNGX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, RARE is priced at $33.82, while TNGX trades at $31.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas TNGX's P/E ratio is -37.42. In terms of profitability, RARE's ROE is +15.67%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, RARE is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check TNGX's competition here
RARE vs CPRX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, RARE is priced at $33.82, while CPRX trades at $31.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas CPRX's P/E ratio is 11.32. In terms of profitability, RARE's ROE is +15.67%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, RARE is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CPRX's competition here
RARE vs TLX Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, RARE is priced at $33.82, while TLX trades at $11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas TLX's P/E ratio is -605.43. In terms of profitability, RARE's ROE is +15.67%, compared to TLX's ROE of -0.02%. Regarding short-term risk, RARE is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check TLX's competition here
RARE vs RYZB Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RARE is priced at $33.82, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RARE's ROE is +15.67%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RARE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RYZB's competition here
RARE vs CBAY Comparison July 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RARE is priced at $33.82, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.54, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RARE's ROE is +15.67%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RARE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CBAY's competition here